Silodosin Causes Impaired Ejaculation and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Bozkurt, Ozan; Demir, Ömer; Şen, Volkan; Esen, Adil

doi:10.1016/j.urology.2015.01.011

Cited by 16 publications

(12 citation statements)

References 26 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This should be attributed to the high selectivity for a 1A -receptors of this molecule that prevents vas deferens contractions and semen emission rather than causing retrograde ejaculation. 5,[9][10][11][18][19][20][21] Nevertheless, patients experiencing ejaculatory dysfunction usually experience greater improvements in LUTS-related symptoms. 22,23 Roehrborn et al showed that patients with ejaculatory dysfunction had a twofold increase in the probability of achieving an improvement ≥3 points in IPSS and ≥3 mL/s in maximum urinary flow rate as compared with patients who maintained preserved ejaculatory function.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

et al. 2016

View full text Add to dashboard Cite

Objectives: To assess the benefit-risk balance of silodosin in a real-life setting of benign prostatic hyperplasia patients with lower urinary tract symptoms. Methods: A phase IV trial including men aged ≥60 years with a clinical diagnosis of benign prostatic hyperplasia with an International Prostate Symptom Score ≥12 was carried out. Patients received silodosin 8 mg for 24 weeks. The primary end-point was a decrease ≥25% in the total International Prostate Symptom Score. Secondary end-points were: changes in total, storage and voiding, and quality of life International Prostate Symptom Scores; changes in the International Continence Society-male questionnaire; changes in the frequency/volume chart; and satisfaction according to the Patient Perception of Study Medication questionnaire. Treatment-emergent adverse events were recorded. Results: Overall, 1036 patients were enrolled. Of these, 766 patients (77.1%) had a decrease ≥25% in the total International Prostate Symptom Score. The mean total International Prostate Symptom Score, and storage and voiding symptoms subscores decreased from 18.9, 8.1 and 10.8 to 10.6, 4.9 and 5.7. Nocturia decreased from 85.7% to 52.4%. The mean International Prostate Symptom Score quality of life score decreased from 4.0 to 2.2. Half of the patients reported an improvement in the frequency and bothersomeness of the most frequent symptoms reported at baseline (all P < 0.001). A reduction in the number of voids was documented by the frequency/volume chart data. The most common treatment-emergent adverse event was ejaculation failure (185 patients; 17.9%), which led to study discontinuation in 2.4% of patients. Overall, 74.2% of patients were satisfied with the medication. Conclusions: Silodosin improved lower urinary tract symptoms in three out of four patients, including diurnal voiding and storage symptoms, nocturia, and quality of life. This treatment showed a favorable safety profile in this setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Additional TRUS imaging of the seminal vesicles demonstrated a mean doubling of their volume after four weeks of therapy (8.1±6.4 vs . 16.4±8.2 cc) (42). There are conflicting studies whether orgasmic function is impaired in patients taking silodosin.…”

Section: Effect Of Bph Treatments On Ejaculatory Functionmentioning

confidence: 99%

Ejaculatory dysfunction in the treatment of lower urinary tract symptoms

DeLay

Nutt

McVary

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

The link between lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and sexual dysfunction is well established. Sexual dysfunction can encompass both ejaculatory dysfunction (EjD) and erectile dysfunction (ED). Ejaculatory dysfunction can consist of premature ejaculation, delayed ejaculation, retrograde ejaculation, anejaculation, decreased force of ejaculation and pain upon ejaculation. The impact of different medical and surgical therapies on ejaculatory function will be reviewed. We reviewed the various categories of LUTS treatment including the canonical epidemiology and pathophysiology as well as the surgical and medical treatments for LUTS/BPH. We note that most surgeries and several medical treatments have a certain but ill-defined negative impact on ejaculatory function. Several MISTs and selected medical therapies appear to have little impact on EjD. Both EjD and BPH are very common disorders in men under the care of an urologist. It is well documented that there is a clinical association between these two entities. Unfortunately many of the medical treatments and almost all surgical treatment impact the ejaculatory function of the patient. The surgical treatment of BPH often leads to retrograde ejaculation while medical treatment leads to anejaculation.

show abstract

“…That study, however, included patients who were taking silodosin for benign prostate hyperplasia. As silodosin affects enlargement of seminal vesicles (Bozkurt, Demir, Sen, & Esen, ), it could have affected the results.…”

Section: Discussionmentioning

confidence: 99%

Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer

et al. 2019

View full text Add to dashboard Cite

Several endocrinological and physical activities orchestrate men's sexual activities.To determine whether body composition calculated by computed tomography measurements is useful for estimating sexual function, we evaluated sexual function of localised prostate cancer patients using the Sexual Health Inventory for Men score, an original questionnaire, and computed tomography and magnetic resonance imaging.The imaging was performed to determine body composition, particularly the psoas muscle. Univariate and multivariate analyses were performed to identify factors affecting sexual activity. The multivariate analysis showed that the volume of the psoas muscle was significantly correlated with sexual activity (odds ratio [95% confidence interval]) (2.507 [1.029-6.109], p = 0.043) and erectile dysfunction (0.261 [0.098-0.692], p = 0.006). We concluded that the psoas muscle is an important predictor of sexual activity and erectile function. K E Y W O R D Serectile dysfunction, psoas muscle, sexual function, SHIM score

show abstract

Silodosin Causes Impaired Ejaculation and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Cited by 16 publications

References 26 publications

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

Ejaculatory dysfunction in the treatment of lower urinary tract symptoms

Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer

Contact Info

Product

Resources

About